COMPANY PROFILE / iPS CELLS & REGENERATIVE MEDICINE
Allogene Therapeutics
Off-the-shelf cell therapy built from edited donor T cells, not from iPS cells
Allogene Therapeutics is a Nasdaq-listed company developing allogeneic CAR-T cells: T cells from healthy donors that carry a CAR gene and are genome-edited so that they do not attack the patient's body. The key point in the iPS cell and regenerative medicine context is that Allogene is trying to deliver a cell therapy that can be taken from inventory, using donor-derived cells rather than iPS cell-derived ones. It runs its own manufacturing plant in Newark, California, but as of October 2026 it has no approved product and no revenue. This profile relies only on the company's Form 10-K and Form 10-Q filed with the U.S. SEC and on clinical trial registrations, and sets out what it makes, whose technology it borrows and how much it spends on what. It is not medical advice on treatment choices.
- Allogene in 30 seconds, and where it stands in iPS cells and regenerative medicine
- The logo and how the name is written
- Where the company sits in the iPS cell and regenerative medicine landscape
- Scale (a development-stage company with no revenue)
- Resources committed to the field
- Track record so far
- Plans ahead
- What the company is aiming for
- Partnership map
- The technologies and products it offers
- The risks this company carries
- Glossary, references and claim-to-source audit
1. Allogene in 30 seconds, and where it stands in iPS cells and regenerative medicine
California, U.S.210 East Grand Avenue
Genome-editing user (secondary)Editing tools are licensed in from other companies
from healthy donorsTCR removed with TALEN or CRISPR
Pivotal Phase 2 (ALPHA3)No product has been approved yet
Companies involved in iPS cells and regenerative medicine fall into three broad groups: large pharma & strategic partners, genome editing & gene therapy, and iPS cell & cell therapy. Allogene is a company whose primary identity is cell therapy and whose secondary identity is genome editing. Its product candidates are T cells taken from donors, given a CAR gene and then genome-edited so that the T cell receptor (TCR) no longer works Sourced. The important point is that Allogene's lead candidates are not derived from iPS cells. Its only link to iPS cells is a 2019 technology licence from Notch Therapeutics covering iPS cell-derived T and NK cells. In January 2024 Allogene returned the rights to all but one target, and Notch was acquired by Roche in 2025 and dissolved Sourced. This article therefore treats the company as an example of the side that pursues off-the-shelf cell therapy with allogeneic (other-person-derived) cells, without using iPS cells.
2. The logo and how the name is written
A note on names: the legal entity is Allogene Therapeutics, Inc. The logo is a registered trademark of the company, so we have not recreated it with generated imagery; the image used in the header of the official website has been downloaded and placed here. Product candidates are named cema-cel (cemacabtagene ansegedleucel, formerly ALLO-501A), ALLO-316 and ALLO-329. On 1 July 2026 the President and CEO changed from David Chang to Zachary Roberts.
Official site: https://allogene.com/3. Where the company sits in the iPS cell and regenerative medicine landscape
Looked at by mechanism, Allogene combines the following elements. The issues covered in this series' explainers on autologous versus allogeneic cells, CAR-T cells, genome editing, and MHC and universal donor cells all sit side by side inside this one company.
| Mechanism | How Allogene uses it | Category |
|---|---|---|
| Allogeneic (other-person-derived) cell therapy | Uses T cells from healthy donors to build an inventory that can serve many patients. The opposite of autologous CAR-T, which uses the patient's own cells | Sourced |
| Genome editing (TALEN) | For its cancer candidates. Cellectis's TALEN technology inactivates the T cell receptor alpha (TCRα), a design meant to prevent graft-versus-host disease (GvHD) | Sourced |
| Genome editing (CRISPR) | For ALLO-329, aimed at autoimmune disease. Uses a non-exclusive licence to CRISPR technology from Arbor Biotechnologies | Sourced |
| Gene delivery | The CAR gene is introduced into T cells with a viral vector. The cGMP-grade vector material is made by an outside contract manufacturer | Sourced |
| Proprietary rejection-avoidance technology (Dagger) | Adds an anti-CD70 CAR so that the patient's own activated T cells do not clear the infused cells too quickly. The aim is to reduce, or avoid, chemotherapy | Sourced |
| iPS cell-derived cells | The licence from Notch Therapeutics was returned in 2024 apart from one target. None of the company's clinical candidates is iPS cell-derived | Sourced |
4. Scale (a development-stage company with no revenue)
Allogene does not sell a product, and it has no approved product Sourced. Because revenue cannot show its size, we look at R&D spending, losses, cash and headcount.
| US$ millions | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (from collaborations) | 114.1 | 0.2 | 0.1 | 0.0 | 0 |
| R&D expense | 220.2 | 256.4 | 242.9 | 192.3 | 150.2 |
| General and administrative expense | 74.1 | 79.3 | 71.7 | 65.2 | 56.8 |
| Net loss | 182.1 | 340.4 | 327.3 | 257.6 | 190.9 |
| Capital expenditure (purchases of property and equipment) | 21.4 | 5.2 | 1.5 | 0.7 | 0.4 |
Source: SEC EDGAR XBRL (each year's Form 10-K). Revenue does not come from product sales. We could not confirm the breakdown of the US$114.1 million of revenue in 2021 from the disclosures we consulted.
| Latest indicators | Value | As of |
|---|---|---|
| Cash on hand (cash, cash equivalents and investments) | US$423.6 million | 30 June 2026 |
| Accumulated deficit | About US$2.1 billion | 30 June 2026 |
| Net loss, January to June 2026 | US$85.3 million | US$110.7 million a year earlier |
| Employees (of whom R&D and technical operations) | 152 (59) | 2 March 2026 |
| How long the company says its cash will last | Into the first quarter of 2029 | Includes the proceeds of the April 2026 public offering |
R&D spending fell by about 41%, from the 2022 peak of US$256.4 million to US$150.2 million in 2025 Our calculation. Capital expenditure dropped from US$65.96 million in 2020, when Cell Forge 1 was being built, to US$0.39 million in 2025 Our calculation.
5. Resources committed to iPS cells and regenerative medicine
Following the checklist used throughout this series, we sort four points (people, money, outside investments, acquisitions and in-licensing, and links with universities and public funding) by whether the primary sources let us confirm them.
| Aspect | What the primary sources confirm | Status |
|---|---|---|
| People (sites and headcount) | Of 152 employees, 59 work in R&D and technical operations (March 2026). In May 2025 the company cut about 28% (61 people) of its workforce, mainly in manufacturing. The 10-Q says that after the April 2026 offering it increased hiring for manufacturing, clinical development and preparation of a marketing application | Confirmed |
| Money (R&D spending and facilities) | R&D expense in 2025 was US$150.2 million: US$75.5 million internal and US$74.6 million external, of which cema-cel accounted for US$23.4 million. The Cell Forge 1 manufacturing plant is a leased facility of about 118,000 square feet (about 11,000 m², our calculation) | Confirmed |
| Outside investments, acquisitions and in-licensing | Acquired allogeneic CAR-T assets from Pfizer in April 2018. Has licensed in technology from Cellectis (TALEN), Arbor (CRISPR), Notch (iPS-derived T and NK cells; mostly returned in 2024) and Antion (miRNA technology; US$2 million invested in 2023) | Confirmed |
| Universities, research institutions and public funding | Strategic alliance with MD Anderson Cancer Center (October 2020, five years; extended by one year in August 2025; US$6 million remains of a funding commitment of up to US$15 million). Up to US$9.2 million (originally US$15 million) from the California Institute for Regenerative Medicine (CIRM) for ALLO-316 | Confirmed |
| In-house iPS cell research site, or clinical trials of iPS cell-derived candidates | Not mentioned in the 10-K or 10-Q. References to iPS cells are limited to the Notch agreement | Could not be confirmed |
In 2019 Allogene leased a building of about 118,000 square feet to build Cell Forge 1, and in 2020 its capital expenditure reached US$65.96 million Sourced. In May 2025, however, it narrowed its manufacturing activity and cut manufacturing-related staff Sourced. The 10-K explains that the company holds enough cema-cel and ALLO-329 inventory to finish its ongoing trials. Allogeneic cells have the property that one manufacturing run can produce doses for many patients and be stored frozen, so building inventory first lets trials continue even with the plant idled. The flip side is that once a product is approved and moves to commercial production, the idled organisation has to be started up again. The company itself writes that it cannot yet estimate the cost of commercial production in a reliable way, and says restarting manufacturing could require rehiring, retraining, re-establishing processes and regulatory inspection Sourced.
6. Track record so far
| When | What happened | What it means |
|---|---|---|
| November 2017 | Incorporated in Delaware. The founders were executives who led development of the CAR-T therapy Yescarta at Kite Pharma (now part of Gilead) | People with autologous CAR-T experience taking on the allogeneic challenge |
| April 2018 | Acquired allogeneic CAR-T assets from Pfizer (including agreements with Cellectis and Servier) | Secured TALEN editing and CD19 rights |
| February 2019 | Leased a building in Newark (about 118,000 square feet) for a manufacturing plant | Investment in in-house manufacturing |
| November 2019 | Licence agreement with Notch Therapeutics (gene-edited T and NK cells derived from iPS cells) | Its only point of contact with iPS cells |
| October 2020 | Five-year strategic alliance with MD Anderson | Joint clinical and preclinical research |
| December 2020 | Licensed rights to a joint venture covering China and other territories (later Overland Therapeutics) | Development and commercial rights in Asia |
| January 2022 | Alliance with Antion Biosciences on miRNA technology (miCAR) | Next-generation cell design |
| January 2024 | Amended the Notch agreement and returned all but one target. The same month, signed a collaboration agreement with Foresight Diagnostics | A step back from iPS-derived candidates, and a strategy of pairing with MRD testing |
| June 2024 | Started ALPHA3, the pivotal Phase 2 trial of cema-cel | Targets patients who are MRD-positive after first-line treatment |
| October 2024 | ALLO-316 received RMAT designation from the FDA | Progress in solid tumours |
| January to April 2025 | The FDA cleared the IND for ALLO-329, and Fast Track designation was granted for three autoimmune diseases | Expansion beyond cancer |
| May 2025 | Scaled back manufacturing and cut about 28% of employees | Cash concentrated on clinical trials |
| August 2025 | Closed the ALPHA3 arm that added the anti-CD52 antibody ALLO-647 (one Grade 5 adverse event attributed to ALLO-647) | Lymphodepletion limited to standard FC (fludarabine plus cyclophosphamide) |
| December 2025 | An arbitration ruling between Cellectis and Servier ended the licence for the earlier candidate ALLO-501 (rights to cema-cel were kept). The same month, Foresight Diagnostics became part of Natera | Tidying up the rights in its collaborations |
| April 2026 | Announced the interim futility analysis of ALPHA3, followed immediately by a public offering (US$2.00 per share, about US$187.9 million received) | The company says the offering extends its cash into the first quarter of 2029 |
| May 2026 | Terminated the licence with Overland Therapeutics | Ended the Asian joint-venture relationship |
| July 2026 | The ALPHA3 development programme for cema-cel received RMAT and Fast Track designations. The Phase 1 results for ALLO-316 were published in the Journal of Clinical Oncology | Now eligible for expedited-pathway benefits ahead of a marketing application |
7. Plans ahead
ALPHA3 is enrolling at more than 80 sites in the United States, Canada, South Korea and Australia, and is expected to reach about 100 sites once it expands into the European Union. The company writes that it has stepped up hiring to prepare for manufacturing, clinical development and a Biologics License Application (BLA) Sourced. For ALLO-316, it believes it has aligned with the FDA on the design of a registrational trial, but it is still exploring strategic options, including a partnership Sourced.
None of the following appears in the 10-K or 10-Q Not yet confirmed.
The annual production capacity of Cell Forge 1 (how many patients it can supply) / how many patients' worth of investigational product one manufacturing run yields / the cost of commercial production (the company itself says it cannot estimate it) / the timing and price of any approval / the partner for ALLO-316 and the start date of a registrational trial. Estimates from press reports or research firms are not used in this article.
8. What the company is aiming for in iPS cells and regenerative medicine
This section includes things the company does not say directly. We set them out as inferences within what the primary sources support, with the evidence for each.
| What the evidence suggests | Primary information it rests on | Category |
|---|---|---|
| To turn CAR-T from "a drug made patient by patient in a hospital" into "a drug taken from inventory" | The 10-K's wording on off-the-shelf products and on delivering treatment faster, more reliably and at greater scale. At the time of the ALPHA3 interim analysis, about one third of screening and infusions took place at community cancer centres | Sourced |
| It is putting donor T cells at the centre, not iPS cells | All three lead candidates are donor-derived T cells. The iPS-derived technology was returned in 2024 apart from one target | Sourced |
| It is aiming for its first approval on cema-cel alone | Among 2025 external R&D costs, cema-cel (US$23.4 million) is the only candidate named by product. ALLO-316 is looking for a partner | Inference |
| In future it wants cells that can be given without chemotherapy | The Dagger technology is described as designed to reduce or avoid standard lymphodepletion. ALLO-329 is being tested in a cohort without lymphodepletion | Sourced |
| It sees autoimmune disease as its second pillar | ALLO-329 is positioned as one of its three main candidates and has Fast Track designation in three diseases | Inference |
| It is keeping to a policy of owning its manufacturing rather than outsourcing it | It kept the plant even after the cutbacks. The 10-K does, however, mention the possibility of relying on a CDMO (contract development and manufacturing organisation) in future | Inference |
The ALPHA3 patients are people who appear to be in remission after first-line treatment but still have cancer-derived DNA in their blood (MRD). Giving these patients CAR-T "without waiting for relapse" means the product has to be usable as soon as a test comes back positive. Autologous CAR-T, made from the patient's own cells, involves a wait for manufacturing; an allogeneic product made in advance can be taken from inventory. The 10-K reports that in the Phase 1 ALPHA and ALPHA2 trials the median time from enrolment to the start of treatment was 2 days, and contrasts this with autologous CAR-T, which often takes more than a month Sourced. From this we read the existence of an inventory as more than a manufacturing convenience for Allogene: it is the condition that makes the trial design itself work Inference.
9. Partnership map for iPS cells and regenerative medicine
Allogene's partnerships are almost all about bringing technology in. TALEN (Cellectis), CRISPR (Arbor), iPS-derived T and NK cell technology (Notch) and miRNA technology (Antion) are all other companies' technologies. The only case of Allogene licensing technology out was to Overland, the Asian joint venture, and that ended in May 2026 Sourced. The company does not own the gene-editing tools themselves; its emphasis appears to be on how to make cells that combine those tools, and which patients to use them in and how Inference.
10. The technologies and products it offers
There is no approved product. The candidates in development are listed below. All are unapproved investigational products, and neither efficacy nor safety has been established.
| Candidate | Target | Stage (trial name, NCT number) | Primary endpoint |
|---|---|---|---|
| cema-cel (formerly ALLO-501A) Anti-CD19 allogeneic CAR-T | MRD-positive large B-cell lymphoma after first-line treatment | In development (pivotal Phase 2). ALPHA3, NCT06500273. Estimated enrolment on ClinicalTrials.gov is 250 | Event-free survival as determined by an independent review committee |
| ALLO-316 Anti-CD70 allogeneic CAR-T | Advanced or metastatic clear cell renal cell carcinoma | In development (Phase 1). TRAVERSE, NCT04696731. Enrolment complete | Dose-limiting toxicity |
| ALLO-329 Anti-CD19/anti-CD70 allogeneic CAR-T (Dagger technology) | Systemic lupus erythematosus (including lupus nephritis), idiopathic inflammatory myopathy, systemic sclerosis | In development (Phase 1). RESOLUTION, NCT07085104. Enrolling | Safety, including dose-limiting toxicity |
The results published so far all come from small single-arm studies or interim analyses, and do not guarantee approval or treatment benefit.
| Result | Figure | Comparator and time point |
|---|---|---|
| ALPHA3 interim analysis (cema-cel, conversion to MRD-negative) | cema-cel arm 58.3% (7/12); observation arm 16.7% (2/12) | First 24 randomised patients. MRD assessed at day 45. EFS and other primary endpoints remain blinded |
| ALPHA3 interim analysis (change in ctDNA) | Median 97.7% decrease in the cema-cel arm; 26.6% increase in the observation arm | Day 45, versus baseline |
| ALLO-316 (renal cell carcinoma, confirmed response rate) | 25.0% (5/20 patients). 31.3% (5/16) among the 16 with high CD70 expression | Phase 1b expansion cohort, single arm with no comparator. Data cut-off 3 November 2025. IEC-HS-like syndrome in 8 of 22 patients (36.4%) |
The 10-K describes three stages of manufacturing: (1) collecting donor white blood cells, expanding them and introducing the CAR gene with a viral vector; (2) genome editing to inactivate TCRα (and, for some candidates, CD52); and (3) purification, formulation and storage Sourced. From a materials and process standpoint, the following points matter.
First, purification that removes the cells that were not edited. T cells that keep their TCR can cause GvHD, so both editing efficiency and the removal step feed directly into the quality specification (this is our explanation; the company does not disclose process details). Second, the viral vector material is bought from an outside contract manufacturer. The cGMP-grade vector used to introduce the CAR gene is made externally, so there is a supply risk outside the company's own plant Sourced. Third, the cells can be frozen and held as inventory. Because storage becomes part of quality, the cryopreservation medium, the container and cell viability after thawing all affect how usable a product is. The 10-K also says the company invests in improved analytical methods and equipment, but it does not name specific materials.
11. The risks this company carries
| Risk | Details | Category |
|---|---|---|
| No approved product yet | No revenue, and an accumulated deficit of about US$2.1 billion. The company says its cash lasts into the first quarter of 2029 | Sourced |
| First approval depends on a single trial | The outlook for the company will change greatly depending on the ALPHA3 result for cema-cel. The 10-Q notes that interim EFS results may not be disclosed in order to keep the study blinded | Sourced |
| Safety events | One Grade 5 adverse event in the ALPHA3 arm combined with ALLO-647 led to the end of ALLO-647's development. IEC-HS-like syndrome was reported in 8 of 22 patients with ALLO-316 | Sourced |
| A single manufacturing site | Cell Forge 1 is the only plant. If it became unusable the company would have to search for a CDMO again. There is also the effort of restarting after the cutbacks | Sourced |
| Reliance on others for editing technology | TALEN comes from Cellectis and CRISPR from Arbor. An arbitration between Cellectis and Servier has already ended the licence for ALLO-501 | Sourced |
| Allogeneic cells may be rejected | The patient's immune system clears the infused cells, so the design relies on lymphodepletion (chemotherapy) and the Dagger technology to create a window in which the cells can persist. Whether that works has to be confirmed in trials | Sourced |
| Commercial production cost is unknown | The company itself writes that it cannot estimate the cost of commercial production in a reliable way | Sourced |
12. Glossary
- Allogeneic
- Using cells from another person (a donor). Contrasted with "autologous", which uses the patient's own cells.
- CAR-T cell
- A T cell given an artificial receptor (CAR) that recognises a marker on cancer cells or other targets.
- TCR (T cell receptor)
- The receptor T cells use to recognise their targets. In allogeneic cells it is inactivated so that they do not attack the patient's tissues.
- GvHD
- Graft-versus-host disease. A reaction in which infused T cells from another person attack the patient's normal tissues.
- TALEN / CRISPR
- Genome-editing tools that cut specific DNA sequences. For the candidates in this article, both are licensed in from other companies.
- MRD
- Minimal residual disease. Traces of cancer left in the body that ordinary imaging cannot see. It is checked with tests such as cancer-derived DNA in the blood.
- EFS
- Event-free survival. The time until an event such as relapse or progression of disease occurs.
- RMAT
- Regenerative Medicine Advanced Therapy. An FDA programme that speeds up the development and review of regenerative medicine products. Designation does not mean approval.
- Dagger technology
- A design that adds an anti-CD70 CAR to prevent the patient's activated T cells from clearing the infused cells too early.
- IEC-HS
- Immune effector cell-associated haemophagocytic lymphohistiocytosis-like syndrome. An excessive immune reaction that can occur after CAR-T infusion.
13. References
- Allogene Therapeutics Form 10-K for the fiscal year ended December 31, 2025 (filed with the U.S. SEC on 12 March 2026). Business description, manufacturing, collaboration agreements, headcount, breakdown of R&D expense, CIRM grant and risks. https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm
- Allogene Therapeutics Form 10-Q for the quarterly period ended June 30, 2026 (filed with the U.S. SEC on 12 August 2026). ALPHA3 interim analysis, the ALLO-316 paper, ALLO-329, termination of the Overland agreement, the public offering and cash on hand. https://www.sec.gov/Archives/edgar/data/1737287/000162828026056213/allo-20260630.htm
- U.S. SEC EDGAR XBRL company facts API (CIK 0001737287). Revenue, R&D expense, G&A expense, net loss and capital expenditure for 2021 to 2025. https://data.sec.gov/api/xbrl/companyfacts/CIK0001737287.json
- ClinicalTrials.gov NCT06500273 (ALPHA3: Phase 2 of cema-cel. The primary endpoint is event-free survival as determined by an independent review committee). https://clinicaltrials.gov/study/NCT06500273
- ClinicalTrials.gov NCT07085104 (RESOLUTION: Phase 1 of ALLO-329. The primary endpoint is safety, including dose-limiting toxicity). https://clinicaltrials.gov/study/NCT07085104
- ClinicalTrials.gov NCT04696731 (TRAVERSE: Phase 1 of ALLO-316. The primary endpoint is dose-limiting toxicity). https://clinicaltrials.gov/study/NCT04696731
- Allogene Therapeutics Official website (to confirm the company profile and logo). https://allogene.com/
14. Claim-to-source audit
| Claim in the article | Category | Source |
|---|---|---|
| Legal name, incorporation, head office address, listing venue | Sourced | References 1 and 7 https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm https://allogene.com/ |
| 152 employees (59 in R&D and technical operations); cut of about 28% (61 people) in May 2025 | Sourced | References 1 and 2 https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm https://www.sec.gov/Archives/edgar/data/1737287/000162828026056213/allo-20260630.htm |
| Revenue, R&D expense, G&A expense, net loss and capital expenditure for 2021 to 2025 | Sourced | References 3 and 1 https://data.sec.gov/api/xbrl/companyfacts/CIK0001737287.json https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm |
| Breakdown of R&D expense (US$75.5 million internal, US$74.6 million external, of which US$23.4 million for cema-cel) | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm |
| Cash on hand of US$423.6 million, accumulated deficit of about US$2.1 billion, cash lasting into the first quarter of 2029 | Sourced | Reference 2 https://www.sec.gov/Archives/edgar/data/1737287/000162828026056213/allo-20260630.htm |
| April 2026 public offering (US$2.00 per share, about US$187.9 million in net proceeds) | Sourced | Reference 2 https://www.sec.gov/Archives/edgar/data/1737287/000162828026056213/allo-20260630.htm |
| Products are allogeneic CAR-T cells. TCR inactivated with TALEN (Cellectis) and CRISPR (Arbor) | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm |
| Three stages of manufacturing (collection and gene introduction, genome editing, purification, formulation and storage) | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm |
| Cell Forge 1 is the only manufacturing site. Leased, about 118,000 square feet. Vector material is made externally | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm |
| The company says inventory is enough to complete ongoing trials after the manufacturing cutback. It cannot estimate commercial production cost | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm |
| Design of ALPHA3 (about 220 people randomised, comparison with an observation arm, EFS as the primary endpoint) | Sourced | References 1 and 2 https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm https://www.sec.gov/Archives/edgar/data/1737287/000162828026056213/allo-20260630.htm |
| ALPHA3 interim analysis (MRD-negative conversion 58.3% versus 16.7%, change in ctDNA) | Sourced | Reference 2 https://www.sec.gov/Archives/edgar/data/1737287/000162828026056213/allo-20260630.htm |
| ALPHA3: interim EFS analysis in mid-2027, enrolment complete at the end of 2027, primary analysis in mid-2028 | Sourced | Reference 2 https://www.sec.gov/Archives/edgar/data/1737287/000162828026056213/allo-20260630.htm |
| Estimated enrolment of 250 and the primary endpoint of NCT06500273 | Sourced | Reference 4 https://clinicaltrials.gov/study/NCT06500273 |
| ALLO-316 results (confirmed response rate 25.0%, IEC-HS 36.4%) and alignment with the FDA on the registrational trial design | Sourced | Reference 2 https://www.sec.gov/Archives/edgar/data/1737287/000162828026056213/allo-20260630.htm |
| Primary endpoint of NCT04696731 | Sourced | Reference 6 https://clinicaltrials.gov/study/NCT04696731 |
| ALLO-329 design (single insertion at the TRAC site, two lymphodepletion regimens) and timing of data updates | Sourced | References 1 and 2 https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm https://www.sec.gov/Archives/edgar/data/1737287/000162828026056213/allo-20260630.htm |
| Primary endpoint of NCT07085104 | Sourced | Reference 5 https://clinicaltrials.gov/study/NCT07085104 |
| Return of the Notch agreement (iPS cell-derived T and NK cells); Roche's acquisition and dissolution of Notch | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm |
| Arbitration ruling between Cellectis and Servier; end of the ALLO-501 licence | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm |
| MD Anderson alliance; CIRM grant (up to US$9.2 million) | Sourced | References 1 and 2 https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm https://www.sec.gov/Archives/edgar/data/1737287/000162828026056213/allo-20260630.htm |
| Termination of the Overland licence (May 2026); holding of about 3% | Sourced | Reference 2 https://www.sec.gov/Archives/edgar/data/1737287/000162828026056213/allo-20260630.htm |
| MRD testing collaboration with Foresight Diagnostics (commitment of about US$37.3 million in spending) | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm |
| Timing of RMAT and Fast Track designations | Sourced | References 1 and 2 https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm https://www.sec.gov/Archives/edgar/data/1737287/000162828026056213/allo-20260630.htm |
| Change of CEO (1 July 2026) | Sourced | Reference 2 https://www.sec.gov/Archives/edgar/data/1737287/000162828026056213/allo-20260630.htm |
| Fall in R&D expense (about 41%), fall in capital expenditure from its peak, conversion of plant area | Our calculation | Calculated for this article from the figures in references 3 and 1 |
| The three-type classification, and the framing of Allogene as primarily cell therapy and secondarily genome editing | Our calculation | This article's own classification |
| Production capacity of Cell Forge 1, patients per manufacturing run, timing and price of approval | Not yet confirmed | Not stated in reference 1 https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm |
| Partner for ALLO-316 and start date of a registrational trial | Not yet confirmed | Not stated in reference 2 https://www.sec.gov/Archives/edgar/data/1737287/000162828026056213/allo-20260630.htm |
| Clinical trials of iPS cell-derived candidates, or an in-house iPS cell research site | Not yet confirmed | Not stated in reference 1 https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm |
| The reading that the existence of an allogeneic inventory is a condition that makes the trial design work | Inference | This article's interpretation, based on the description of ALPHA2 in reference 1 |
| The reading that it is aiming for its first approval on cema-cel alone | Inference | This article's interpretation, based on the breakdown of external R&D costs in reference 1 |
| The reading that it sees autoimmune disease as its second pillar | Inference | This article's interpretation, based on the positioning of ALLO-329 in references 1 and 2 |
| The reading that it is keeping to a policy of owning its manufacturing | Inference | This article's interpretation, based on the description of manufacturing strategy in reference 1 |
| The reading that its partnerships mostly bring technology in, with emphasis on how cells are made and used rather than on developing tools | Inference | This article's interpretation, based on the descriptions of the collaboration agreements in references 1 and 2 |
| Explanation from the viewpoint of purification, cryopreservation and materials | Inference | This article's own explanation; the company does not disclose process details |
Last updated 1 October 2026 / Troy Technical
Every figure in this article comes from the statutory filings Allogene Therapeutics has made with the U.S. Securities and Exchange Commission (SEC) and from ClinicalTrials.gov registrations. No research-firm estimates or press-based figures have been used. Passages marked "Inference" are this article's interpretation of the primary sources, not statements made by the company. This article is not medical advice, does not recommend any particular treatment or product, and makes no comparison of its merits with other companies' products.